Routine Gene Testing For Plavix Patients Unsupported By Evidence - ACC/AHA
This article was originally published in The Gray Sheet
Executive Summary
The evidence base is insufficient to support routine genetic or platelet function testing to assess a patient's responsiveness to the anti-clotting drug clopidogrel, according to new cardiovascular society guidelines
You may also be interested in...
Research In Brief
NIH-funded clinical trial publication rates sub-par, gaps in skin substitute products data, and more research news.
Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care PMA Filed
Nanosphere submitted a PMA late last month for the first point-of-care assay that could make genotyping a more feasible routine tool to guide antiplatelet therapy
Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care PMA Filed
Nanosphere submitted a PMA late last month for the first point-of-care assay that could make genotyping a more feasible routine tool to guide antiplatelet therapy